ArticleEndocrine pathology2026
Clinical and Pathological Features of EC-cell Familial Small Intestine Neuroendocrine Tumors: A Nationwide Cohort From the French GTE-RENATEN Network.
Article in Endocrine pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EC-cell familial small intestine neuroendocrine tumors (EC-cell F-SINET) are a recently described but poorly characterized entity. We aimed to describe their clinical and pathological features, and to compare them to patients with a sporadic form (EC-cell S-SINET). We constituted a nationwide cohort including (retrospectively patients diagnosed before 2012 and prospectively from 2012 to 2022) all patients with F-SINET (histologically proven SINET in ≥ 2 first or second-degree relatives) managed in the French GTE-RENATEN network. Clinical and pathological data were described and compared to the GTE-RENATEN population-based cohort including 2460 patients with EC-cell S-SINET using multivariable logistic regression. The survival impact of EC-cell F-SINET was explored using Cox proportional hazard analyses. We included 92 patients with EC-cell F-SINET from 47 families. Median age at diagnosis was 60.4 years. Among these patients, 22% had a history of another cancer, 76.1% had synchronous or metachronous metastases, 38% had a carcinoid tumor syndrome, and median Ki-67 labeling index was 2%. Median survival was 204.6 months. Multifocal EC-cell SINET were present in 66.7% of patients with EC-cell F-SINET and were associated with poorer prognosis (p = 0.005). In comparison with EC-cell S-SINET patients, those with EC-cell F-SINET had more frequent multifocal primary tumor in the small bowel (p < 0.0001) and carcinoid syndrome (p = 0.038), lower Ki-67 index and tended to be younger (p = 0.094). After adjustment on independent prognostic factors (age at diagnosis, metastatic stage, carcinoid tumor syndrome and Ki-67 index), EC-cell F-SINET did not have a different prognosis than that of EC-cell S-SINET. Patients with EC-cell F-SINET are characterized by more frequent multifocal EC-cell SINETs and more frequent carcinoid tumor syndrome, but their prognosis seems similar compared to patients with EC-cell S-SINET.
Indexed as
Identifiers
41854801What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.